Agenus Inc. (AGEN)
NASDAQ: AGEN · Real-Time Price · USD
7.16
+0.03 (0.42%)
Sep 15, 2026, 4:00 PM EDT - Market closed
Agenus Employees
Agenus had 81 employees as of December 31, 2025. The number of employees decreased by 235 or -74.37% compared to the previous year.
Employees
81
Change (1Y)
-235
Growth (1Y)
-74.37%
Revenue / Employee
$1,638,185
Profits / Employee
$1,133,272
Market Cap
322.35M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 81 | -235 | -74.37% |
| Dec 31, 2024 | 316 | -73 | -18.77% |
| Dec 31, 2023 | 389 | -144 | -27.02% |
| Dec 31, 2022 | 533 | 92 | 20.86% |
| Dec 31, 2021 | 441 | 82 | 22.84% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| Abeona Therapeutics | 226 |
| Lyell Immunopharma | 161 |
| Zentalis Pharmaceuticals | 106 |
| SAB Biotherapeutics | 86 |
| Upstream Bio | 75 |
| InflaRx | 65 |
| Vicore Pharma Holding AB | 46 |
AGEN News
- 4 days ago - Agenus files to sell 221,525 shares of common stock for holders - TheFly
- 4 days ago - Agenus Registration statement: Registration filing - Filings
- 5 days ago - Agenus Transcript: Investor update - Transcripts
- 5 days ago - Agenus Slides: Investor update - Filings
- 5 days ago - Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 - Business Wire
- 8 days ago - Agenus Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 15 days ago - Agenus to Participate in Upcoming September Investor Conferences - Business Wire
- 18 days ago - Agenus Announces Peer-Reviewed Publication Linking BOT+BAL's Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism - Business Wire